targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure
Published 5 years ago • 161 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
8:55
options for mrcc after nivolumab
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
2:08
nivolumab with ipilimumab for mrcc
-
1:55
investigating responses to nivolumab and ipilimumab in advanced rcc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
1:52
efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma
-
1:56
nivolumab and ipilimumab for advanced bcvh
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
2:52
frontline therapy options for mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
1:33
checkmate 920: nivolumab plus ipilimumab for renal cell cancer
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
4:39
nivolumab and ipilimumab for metastatic kidney cancer
-
3:45
combination immunotherapy in newly diagnosed mrcc
-
9:09
nivolumab with alternatively scheduled ipilimumab in first-line treatment of advanced rcc